Literature DB >> 21451412

Mediators of pruritus during cholestasis.

Ronald P J Oude Elferink1, Andreas E Kremer, Ulrich Beuers.   

Abstract

PURPOSE OF REVIEW: Pruritus is a frequent symptom in patients with cholestatic liver diseases. Itching may be excruciating, may seriously impair quality of life and even induce suicidal ideation in the most severe cases. RECENT
FINDINGS: The molecular mechanism of itch signal transduction in cholestasis is largely unclear. It may be caused or potentiated by compounds that accumulate in the circulation during cholestasis, which either directly or indirectly affect signalling in itch fibres. In the past, bile salts and endogenous opioids have been proposed but never been proven to be key factors in itch perception during cholestasis. We have performed a screen for compounds in plasma from patients with various cholestatic conditions for their capacity to activate neuronal cell lines. In these sera, we could identify a potent neuronal activator as lysophosphatidic acid (LPA). LPA is a very potent signalling phospholipid that can activate cells through various LPA receptors. Quite strikingly, samples from itchy cholestatic patients contained higher amounts of LPA. These increased levels of LPA turned out to be caused by elevated levels of serum autotaxin, the enzyme that converts lysophosphatidylcholine into LPA. This is a striking finding, as autotaxin has never been connected to itch perception thus far. We have also shown that LPA, when injected intradermally, caused scratching behaviour in mice.
SUMMARY: On the basis of our results, we hypothesize that during cholestasis expression of autotaxin is induced, which gives rise to increased local formation of LPA near unmyelinated nerve endings of itch fibres. LPA activates these neurons through one of the LPA receptors, which in turn potentiates action potentials along itch fibres leading to the perception of pruritus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21451412     DOI: 10.1097/MOG.0b013e32834575e8

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  8 in total

1.  Management of pruritus in patients with cholestatic liver disease.

Authors:  Cynthia Levy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

2.  Pruritus in the elderly: clinical approaches to the improvement of quality of life.

Authors:  Kenneth R Cohen; Jerry Frank; Rebecca L Salbu; Igor Israel
Journal:  P T       Date:  2012-04

Review 3.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

4.  Bile acids in a multicenter, population-based case-control study of stillbirth.

Authors:  Robert M Silver; Corette B Parker; Robert Goldenberg; Uma M Reddy; Donald J Dudley; George R Saade; Carol J Rowland Hogue; Donald Coustan; Michael W Varner; Matthew A Koch; Deborah Conway; Radek Bukowski; Halit Pinar; Barbara Stoll; Janet Moore; Marian Willinger
Journal:  Am J Obstet Gynecol       Date:  2013-11-08       Impact factor: 8.661

5.  The impact of intensified hemodialysis on pruritus in an end stage renal disease patient with biliary ductopenia.

Authors:  Sandra Chomicki; Omar Dahmani
Journal:  Case Rep Nephrol       Date:  2015-03-04

6.  Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats.

Authors:  Bin Tian; Xue-Long Wang; Ya Huang; Li-Hua Chen; Ruo-Xiao Cheng; Feng-Ming Zhou; Ran Guo; Jun-Cheng Li; Tong Liu
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

Review 7.  Pruritus in autoimmune connective tissue diseases.

Authors:  Hee Joo Kim
Journal:  Ann Transl Med       Date:  2021-03

Review 8.  Cholestatic pruritus: a knowledge update.

Authors:  Thaís Reginatto Nietsche; Gabriel Dotta; Carlos Baptista Barcaui; Maria Lúcia Cardoso Gomes Ferraz
Journal:  An Bras Dermatol       Date:  2022-03-09       Impact factor: 2.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.